255 related articles for article (PubMed ID: 33291667)
21. Advanced glycation end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36.
Unno Y; Sakai M; Sakamoto Y; Kuniyasu A; Nakayama H; Nagai R; Horiuchi S
Biochem Biophys Res Commun; 2004 Dec; 325(1):151-6. PubMed ID: 15522213
[TBL] [Abstract][Full Text] [Related]
22. DNA aptamer raised against receptor for advanced glycation end products suppresses renal tubular damage and improves insulin resistance in diabetic mice.
Sotokawauchi A; Matsui T; Higashimoto Y; Nishino Y; Koga Y; Yagi M; Yamagishi SI
Diab Vasc Dis Res; 2021; 18(1):1479164121990533. PubMed ID: 33535822
[TBL] [Abstract][Full Text] [Related]
23. Uptake of oxidized low-density lipoprotein in a THP-1 cell line lacking scavenger receptor A.
Sugano R; Yamamura T; Harada-Shiba M; Miyake Y; Yamamoto A
Atherosclerosis; 2001 Oct; 158(2):351-7. PubMed ID: 11583713
[TBL] [Abstract][Full Text] [Related]
24. Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway.
Geng J; Yang C; Wang B; Zhang X; Hu T; Gu Y; Li J
Biomed Pharmacother; 2018 Jan; 97():941-947. PubMed ID: 29136772
[TBL] [Abstract][Full Text] [Related]
25. ALDH2 deficiency inhibits Ox-LDL induced foam cell formation via suppressing CD36 expression.
Wei S; Zhang L; Bailu Wang ; Zhao Y; Dong Q; Pan C; Li C; He D; Yuan Q; Xu F; Chen Y
Biochem Biophys Res Commun; 2019 Apr; 512(1):41-48. PubMed ID: 30853183
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized ldl: a possible role for interleukin-6.
Keidar S; Heinrich R; Kaplan M; Hayek T; Aviram M
Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1464-9. PubMed ID: 11557673
[TBL] [Abstract][Full Text] [Related]
27. GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A.
Dai Y; Dai D; Wang X; Ding Z; Li C; Mehta JL
J Cardiovasc Pharmacol; 2014 Jul; 64(1):47-52. PubMed ID: 24705175
[TBL] [Abstract][Full Text] [Related]
28. Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol.
Xu L; Wang YR; Li PC; Feng B
Lipids Health Dis; 2016 Sep; 15(1):161. PubMed ID: 27644038
[TBL] [Abstract][Full Text] [Related]
29. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy.
Matsui T; Higashimoto Y; Nishino Y; Nakamura N; Fukami K; Yamagishi SI
Diabetes; 2017 Jun; 66(6):1683-1695. PubMed ID: 28385802
[TBL] [Abstract][Full Text] [Related]
30. Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis.
Hayek T; Kaplan M; Raz A; Keidar S; Coleman R; Aviram M
Atherosclerosis; 2002 Mar; 161(1):65-74. PubMed ID: 11882318
[TBL] [Abstract][Full Text] [Related]
31. Identification on human CD36 of a domain (155-183) implicated in binding oxidized low-density lipoproteins (Ox-LDL).
Puente Navazo MD; Daviet L; Ninio E; McGregor JL
Arterioscler Thromb Vasc Biol; 1996 Aug; 16(8):1033-9. PubMed ID: 8696943
[TBL] [Abstract][Full Text] [Related]
32. Recombinant glutathione S-transferase/CD36 fusion proteins define an oxidized low density lipoprotein-binding domain.
Pearce SF; Roy P; Nicholson AC; Hajjar DP; Febbraio M; Silverstein RL
J Biol Chem; 1998 Dec; 273(52):34875-81. PubMed ID: 9857015
[TBL] [Abstract][Full Text] [Related]
33. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta.
Nakata A; Nakagawa Y; Nishida M; Nozaki S; Miyagawa J; Nakagawa T; Tamura R; Matsumoto K; Kameda-Takemura K; Yamashita S; Matsuzawa Y
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1333-9. PubMed ID: 10323787
[TBL] [Abstract][Full Text] [Related]
34. Fructose causes endothelial cell damage via activation of advanced glycation end products-receptor system.
Sotokawauchi A; Matsui T; Higashimoto Y; Yamagishi SI
Diab Vasc Dis Res; 2019 Nov; 16(6):556-561. PubMed ID: 31375034
[TBL] [Abstract][Full Text] [Related]
35. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions.
Podrez EA; Poliakov E; Shen Z; Zhang R; Deng Y; Sun M; Finton PJ; Shan L; Febbraio M; Hajjar DP; Silverstein RL; Hoff HF; Salomon RG; Hazen SL
J Biol Chem; 2002 Oct; 277(41):38517-23. PubMed ID: 12145296
[TBL] [Abstract][Full Text] [Related]
36. Oxidized LDL activated eosinophil polarize macrophage phenotype from M2 to M1 through activation of CD36 scavenger receptor.
Qin M; Wang L; Li F; Yang M; Song L; Tian F; Yukht A; Shah PK; Rothenberg ME; Sharifi BG
Atherosclerosis; 2017 Aug; 263():82-91. PubMed ID: 28623741
[TBL] [Abstract][Full Text] [Related]
37. Varenicline enhances oxidized LDL uptake by increasing expression of LOX-1 and CD36 scavenger receptors through α
Kanaoka Y; Koga M; Sugiyama K; Ohishi K; Kataoka Y; Yamauchi A
Toxicology; 2017 Apr; 380():62-71. PubMed ID: 28202387
[TBL] [Abstract][Full Text] [Related]
38. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36.
Han J; Hajjar DP; Febbraio M; Nicholson AC
J Biol Chem; 1997 Aug; 272(34):21654-9. PubMed ID: 9261189
[TBL] [Abstract][Full Text] [Related]
39. IRAK regulates macrophage foam cell formation by modulating genes involved in cholesterol uptake and efflux.
Rana M; Kumar A; Tiwari RL; Singh V; Chandra T; Dikshit M; Barthwal MK
Bioessays; 2016 Jul; 38(7):591-604. PubMed ID: 27270491
[TBL] [Abstract][Full Text] [Related]
40. The atheroprotective role of lipoxin A
Mai J; Liu W; Fang Y; Zhang S; Qiu Q; Yang Y; Wang X; Huang T; Zhang H; Xie Y; Lin M; Chen Y; Wang J
Atherosclerosis; 2018 Nov; 278():259-268. PubMed ID: 30340110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
